Neutralizing antibodies generated during natural hiv-1 infection: Good news for an hiv-1 vaccine?

Nature Medicine

Volumn 15, Issue 8, 2009, Pages 866-870

  Stamatatos, Leonidas ^a,b   Morris, Lynn ^c,d   Burton, Dennis R ^e   Mascola, John R ^f  

^a SEATTLE BIOMEDICAL RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES   (South Africa)

^d South Africa Inst Medical Research   (South Africa)

^e SCRIPPS RESEARCH INSTITUTE   (United States)

^f NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE; VIRUS ANTIBODY;

ANIMAL; BIOLOGICAL MODEL; BIOSYNTHESIS; BLOOD; EPITOPE MAPPING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; METABOLISM; REVIEW;

AIDS VACCINES; ANIMALS; ANTIBODIES, VIRAL; EPITOPE MAPPING; HIV INFECTIONS; HIV-1; HUMANS; MODELS, BIOLOGICAL;

EID: 69149083668     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.1949     Document Type: Article

References (46)

1. Plotkin, S.A. Vaccines: Correlates of vaccine-induced immunity. Clin. Infect. Dis. 47, 401-409 (2008).
2. Amanna, I.J., Messaoudi, I. & Slifka, M.K. Protective immunity following vaccination: How is it defined? Hum. Vaccin. 4, 316-319 (2008).
3. Robbins, J.B., Schneerson, R. & Szu, S.C. Perspective: Hypothesis: serum IgG antibody is sufficient to confer protection against infectious diseases by inactivating the inoculum. J. Infect. Dis. 171, 1387-1398 (1995).
4. Burton, D.R. et al. HIV vaccine design and the neutralizing antibody problem. Nat. Immunol. 5, 233-236 (2004).
5. Haynes, B.F. & Montefiori, D.C. Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates. Expert Rev. Vaccines 5, 579-595 (2006).
6. Mascola, J.R. et al. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. J. Infect. Dis. 173, 340-348 (1996).
7. Flynn, N.M. et al. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J. Infect. Dis. 191, 654-665 (2005).
8. Letvin, N.L. Progress and obstacles in the development of an AIDS vaccine. Nat. Rev. Immunol. 6, 930-939 (2006).
9. Barouch, D.H. Challenges in the development of an HIV-1 vaccine. Nature 455, 613-619 (2008).
10. Koup, R.A. et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J. Virol. 68, 4650-4655 (1994).
11. Buchbinder, S.P. et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): A double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372, 1881-1893 (2008).
12. Wei, X. et al. Antibody neutralization and escape by HIV-1. Nature 422, 307-312 (2003).
13. Cheng-Mayer, C., Homsy, J., Evans, L.A. & Levy, J.A. Identification of human immunodeficiency virus subtypes with distinct patterns of sensitivity to serum neutralization. Proc. Natl. Acad. Sci. USA 85, 2815-2819 (1988).
14. Kostrikis, L.G., Cao, Y., Ngai, H., Moore, J.P. & Ho, D.D. Quantitative analysis of serum neutralization of human immunodeficciency virus type 1 from subtypes A, B, C, D, E, F and I: Lack of direct correlation between neutralization serotypes and genetic subtypes and evidence for prevalent serum-dependent infectivity enhancement. J. Virol. 70, 445-458 (1996).
15. Moore, J.P. et al. Inter-and intraclade neutralization of human immunodeficiency virus type 1: Genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 serotypes. J. Virol. 70, 427-444 (1996).
16. Brown, B.K. et al. Cross-clade neutralization patterns among HIV-1 strains from the six major clades of the pandemic evaluated and compared in two different models. Virology 375, 529-538 (2008).
17. Rademeyer, C. et al. Genetic characteristics of HIV-1 subtype C envelopes inducing cross-neutralizing antibodies. Virology 368, 172-181 (2007).
18. Li, M. et al. Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular Env clones from acute and early hetero-sexually acquired infections in Southern Africa. J. Virol. 80, 11776-11790 (2006).
19. Dhillon, A.K. et al. Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors. J. Virol. 81, 6548-6562 (2007).
20. Li, Y. et al. Broad HIV-1 neutralization mediated by CD4-binding site antibodies. Nat. Med. 13, 1032-1034 (2007).
21. Baba, T.W. et al. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat. Med. 6, 200-206 (2000).
22. Mascola, J.R. et al. Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J. Virol. 73, 4009-4018 (1999).
23. Mascola, J.R. et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat. Med. 6, 207-210 (2000).
24. Parren, P.W. et al. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J. Virol. 75, 8340-8347 (2001).
25. Shibata, R. et al. Neutralizing antibody directed against the HIV-1 envelope glyco-protein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. Nat. Med. 5, 204-210 (1999).
26. Binley, J.M. et al. Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. J. Virol. 82, 11651-11668 (2008).
27. Doria-Rose, N.A. et al. Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing antibodies. J. Virol. 83, 188-199 (2009).
28. Li, Y. et al. Analysis of the neutralization specificities in polyclonal sera derived from human immunodeficiency virus type-1 infected individuals. J. Virol 83, 1045-1059 (2009).
29. Sather, D.N. et al. Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection. J. Virol. 83, 757-769 (2009).
30. Li, M. et al. Human immunodeficiency virus type 1 Env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J. Virol. 79, 10108-10125 (2005).
31. Simek, D.M. et al. HIV-1 elite neutralizers: Individuals with broad and potent neutralizing activity identified using a high throughput neutralization assay together with an analytical selection algorithm. J. Virol. published online, doi: 10.1128/JVI. 00110-09 (13 May 2009).
32. Barbas, C.F., III et al. Recombinant human Fab fragments neutralize human type 1 immunodeficiency virus in vitro. Proc. Natl. Acad. Sci. USA 89, 9339-9343 (1992).
33. Burton, D.R. et al. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 266, 1024-1027 (1994).
34. Decker, J.M. et al. Antigenic conservation and immunogenicity of the HIV coreceptor binding site. J. Exp. Med. 201, 1407-1419 (2005).
35. Gray, E.S. et al. Neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype C infection. J. Virol. 81, 6187-6196 (2007).
36. Labrijn, A.F. et al. Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1. J. Virol. 77, 10557-10565 (2003).
37. Zwick, M.B. et al. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J. Virol. 75, 10892-10905 (2001).
38. Shen, X. et al. In Vivo gp41 Antibodies targeting the 2F5 mAb epitope mediate HIV-1 neutralization breadth. J. Virol. 83, 3617-3625 (2009).
39. Haynes, B.F. et al. Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science 308, 1906-1908 (2005).
40. Sanders, R.W. et al. The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120. J. Virol. 76, 7293-7305 (2002).
41. Scanlan, C.N. et al. The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of α1 → 2 mannose residues on the outer face of gp120. J. Virol. 76, 7306-7321 (2002).
42. Calarese, D.A. et al. Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science 300, 2065-2071 (2003).
43. Hessell, A.J. et al. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog. published online, doi:10.1371/journal.ppat.1000433 (15 May 2009).
44. Hessell, A.J. et al. Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat. Med. advance online publication, doi:10.1038/nm.1974 (7 June 2009).
45. Tiller, T. et al. Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning. J. Immunol. Methods 329, 112-124 (2008).
46. Wrammert, J. et al. Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature 453, 667-671 (2008).